Hélicidine 10% is applied in addressing cough patterns related to irritative states. The medicine is used for calming dry coughs and toux d'irritation (irritation coughs), acting as a peripheral antitussive agent.

Managing Dry, Persistent, and Irritative Coughs

Hélicidine 10% is applied in addressing coughs that are classified as dry, irritative, or non-productive. This is relevant for symptoms related to irritative states of the respiratory tract, often associated with acute bronchial conditions or common seasonal infections, where symptoms create noticeable physiological strain. The primary support helps ease this peripheral irritation, which contributes to improved comfort during periods of heightened symptoms.

Support for Annoying Coughs that Interfere with Rest

The syrup is commonly used in clinical settings that involve troublesome symptoms that interfere with daily functioning or affect periods of rest. By providing symptomatic support, this medication helps ease the overall burden of distressing manifestations, supporting the patient during difficult episodes by easing distress.

Dual Benefit for Airway Discomfort

Hélicidine may be considered relevant for easing acute or disruptive symptom patterns, and its property related to thinning bronchial secretions supports general well-being. This property assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic phases.

Quick Fact: Relief for Persistent Irritation
Primary Use: Applied in addressing dry and irritation coughs.
Key Benefit: Supports the patient by easing distress and maintaining functional stability.
Context: Commonly used during acute symptomatic episodes associated with respiratory irritation.

Regulatory References

1. French Public Drug Database (Base de Données Publique des Médicaments)

Eligibility Profile: Who Can and Cannot Use Hélicidine 10%

Official regulatory documents define strict criteria for using Hélicidine 10% syrup based on age, physiological status, and underlying conditions. The medicine is primarily intended for adults and adolescents (aged 15 years and older) experiencing a dry, irritative cough.

Absolute Contraindications

Population Group	Restriction Basis
Infants	Prohibited for children under 2 years old due to risk of aggravating bronchial congestion.
Hypersensitivity	Prohibited with known allergy to the active substance, excipients (such as parabens), or related proteins (e.g., tropomyosin).

Restricted Use and Limitations

Use is strongly advised against for patients with hereditary fructose intolerance due to the maltitol content in the syrup. The medicine must not be used to treat a productive or wet cough (toux grasse), as it is intended only for non-productive cough patterns. Use during pregnancy and lactation is designated as with caution (prudence), requiring consultation with a healthcare professional. Although not contraindicated, those with chronic bronchial conditions must seek re-evaluation if the cough persists or worsens.

Interactions with other medicines and products

The official regulatory profile for Hélicidine 10% syrup is based on the authoritative findings published in government documentation, which detail any specific restrictions or the absence of formally documented drug interactions.

Official Interaction Profile Summary

Interaction Category	Regulatory Status
Specific Drug-Drug Interactions	None formally documented or named in the dedicated interaction section of the label.
Pharmacokinetic Interactions	No specific metabolic (e.g., CYP-enzyme mediated) or transporter-mediated interactions are formally documented.
Food, Alcohol, or Herbal Products	Interactions with food, beverages, and herbal products are explicitly documented as Not Applicable in the regulatory labeling.
Timing Requirements	No mandatory time separation rules are formally documented for co-administered medicinal products.

Pharmacodynamic Interaction Restrictions

While no specific drug combinations are classified as contraindicated, official warnings restrict the co-administration of drug categories with counteracting effects. The regulatory label documents that combining a bronchial mucomodifier (secretolytic) with other antitussives or with secretion-drying substances (such as atropinics) is considered an irrational combination. This is due to the opposing actions of these medicinal product classes.

Regulatory Conclusion

The overall interaction structure is characterized by the formal regulatory declaration of no documented pharmacokinetic or specific drug-drug interactions that would require timing separation or dosage adjustment. The only established constraint is a high-level pharmacodynamic restriction concerning the counteracting effects of co-administered therapeutic classes, as defined in official product labeling.

How Hélicidine 10% Works

Hélicidine's mechanism is a peripheral dual action, modulating afferent signals within the cough reflex arc in the tracheobronchial system.

---

Modulating Airway Tone through Peripheral Bronchorelaxation

The mucoglycoprotein structure of Hélicidine indirectly modulates airway smooth muscle tone. It achieves this by stimulating the localized release of prostaglandin E2 ( PGE2), which activates prostanoid receptors and leads to muscle relaxation. This physiological effect reduces the peripheral sensory input from the airways, which influences tracheobronchial afferent nerve activity. The mechanistic magnitude of this bronchorelaxant action is constrained by the functional activity of COX enzymes, as co-administration of COX inhibitors can attenuate the resulting smooth muscle relaxation.

---

Altering Secretion Dynamics via Secretolytic Action

The drug engages a secretolytic mechanism by physicochemically interacting with the mucins present in bronchial secretions. This interaction reduces the viscosity of the mucus matrix. The resulting physiological consequence is an enhanced mucociliary clearance, which facilitates the clearance of viscous secretions from the airways, thereby reducing physical stimuli.

Hélicidine 10% syrup is an antitussive medicine intended for the symptomatic treatment of non-productive coughs (dry coughs or irritation coughs). The treatment is generally short-term (a few days) and should be taken only when the cough occurs.

Dosage and Administration

This syrup is taken orally. It is important to follow the dose and frequency prescribed by a healthcare professional. Dosing is typically divided into three daily doses.

Patient Category	Weight/Age Range	Recommended Dosage (per day)
Adults	All weights	2 tablespoonfuls 3 times a day
Children	25 to 50 kg (approx. 8 to 15 years)	3 to 5 tablespoonfuls per day
	15 to 25 kg (approx. 4 to 8 years)	1 tablespoonful 3 times a day
	12 to 15 kg (approx. 2 to 4 years)	2 teaspoonfuls 3 times a day

Note: 1 tablespoonful equals 15 mL; 1 teaspoonful equals 5 mL. For children, the dosage is also specified as 2 mL/kg/day, divided into 3 doses.

Important Considerations

• Do not use this medicine for a productive cough (wet cough with sputum), as coughing is a natural defense mechanism for clearing bronchial secretions.
• Do not exceed the recommended dosage.
• If symptoms worsen or persist after a few days, or if the cough is accompanied by fever or sputum, consult a doctor for a re-evaluation of the treatment.

Research evidence / Overview of studies for Hélicidine 10%

Evidence for Chronic Cough Associated with Chronic Obstructive Lung Disease (COPD)

Research was studied for its relevance in conditions involving periods of heightened symptoms, specifically chronic cough that was observed in a select group of adults with stabilized Chronic Obstructive Lung Disease (COPD). The core research was conducted as a short-term, randomized, double-masked, placebo-controlled trial, which was used to explore whether the substance was associated with changes in specific cough outcomes. The primary focus of this research was the objective physiological measurement of cough: researchers monitored the frequency and duration of nocturnal cough episodes using specialized recording equipment.

Research highlights changes measured during the study period when comparing the active substance to an inactive placebo over the short observation period. The study also explored subjective patient-reported outcomes describing perceived discomfort. What remains uncertain is the clinical meaning of the measured changes, particularly given the objective results and the inconsistent subjective reports. Furthermore, sample sizes were modest in the key trial. This means that the results apply only to the populations studied—specifically adults with COPD who met a high threshold for frequent nightly coughing.

Research on General Acute Dry or Irritative Cough

For outcomes capturing phases of heightened symptom activity, such as general dry or irritative cough, research was evaluated in a different manner. These studies often involved randomized non-inferiority trials that used an active comparator in the control group, rather than comparing it directly to a placebo. This research examined patient-reported outcomes describing perceived discomfort, such as changes measured by Quality of Life questionnaires and symptom severity scales, over short treatment durations.

Short-Term Follow-up and Long-Term Data Gaps

Across the research available, efficacy variables were observed in studies conducted for limited follow-up durations, typically observing changes over only a few days. The research generally focuses on symptom patterns and studies monitored responses over these short, defined time intervals. Consequently, the long-term effects are not fully established, and there is limited information regarding the durability of any reported short-term changes or the need for further study regarding extended use.

Main Uncertainties and Areas for Future Research

The research on Hélicidine 10% has several documented limitations that contribute to uncertainty. Key research limitation frames include the fact that sample sizes were modest in the most controlled trials, and evidence quality varies across studies. Furthermore, non-inferiority trials are designed to evaluate whether an active substance is non-inferior to a control, which is a different goal than definitively establishing a result against an inert control (placebo). This highlights what is known—and what is still uncertain—about the medicine's profile. Study results reflect the specific conditions under which they were conducted; research provides context but not individual predictions.

Key Studies & References Hélicidine 10% Monograph - Base de Données Publique des Médicaments (France)

Common questions about Hélicidine 10% (FAQ)

Q: What is Hélicidine 10% used for?

A: Hélicidine 10% is a syrup used to soothe a dry or irritating cough in adults and children. Its active ingredient, hemicellulase, is classified as a cough suppressant (antitussive) that acts to calm the coughing reflex. It is generally intended for short-term use.

---

Q: Does Hélicidine 10% cause drowsiness?

A: Generally, no. Hélicidine 10%, when containing the active ingredient hemicellulase, is typically considered non-sedating and does not usually cause drowsiness. It is important to always check the specific ingredients and package leaflet, as some older or alternative formulations under the same brand name may contain ingredients like oxomemazine, which can cause sedation.

---

Q: Can children take Hélicidine 10%?

A: Hélicidine 10% is generally suitable for use in children, but the appropriate dosage must be determined by the child's age and weight, and it should always be administered under the guidance of a healthcare professional or pharmacist. It is not usually recommended for children under 2 years old unless specifically advised by a doctor.

---

Q: How should I take Hélicidine 10%?

A: Hélicidine 10% is taken orally. The dose and frequency depend on your age and the severity of your cough, and the information is provided on the bottle or in the package leaflet. The syrup is usually measured with a measuring cup or spoon. Do not exceed the recommended dose, and if your cough persists for more than a few days, you should consult a doctor.

---

Q: Can I take Hélicidine 10% if I am pregnant or breastfeeding?

A: If you are pregnant or breastfeeding, you should always consult a doctor or pharmacist before taking any medication, including Hélicidine 10%. While the risks associated with this specific cough suppressant may be low, a healthcare professional must evaluate the potential benefits versus any theoretical risks for your specific situation.

How to Store and Dispose of Hélicidine 10%?

The official storage and disposal requirements for Hélicidine 10% syrup are strictly defined in regulatory documents to maintain stability and ensure environmental safety.

Storage and Stability Requirement	Official Regulatory Mandate
Temperature Control	Store at a temperature below 25°C (room temperature).
Prohibited Environments	Do not refrigerate or do not freeze the syrup.
In-Use Stability	Use the medicine within six months after the initial opening of the bottle.
Container Integrity	Keep the bottle tightly closed and stored in the original outer packaging.
Child Safety	Store the syrup out of the sight and reach of children.
Disposal Protocol	Do not throw away in household waste or wastewater. Expired or unused medicine must be returned to a pharmacist.